All News

gout podagra inflammed

Best Interventions for Gout Flares

Jack Cush, MD

A recent metanalysis assessed the comparative efficacy of current first-line pharmacologic antiinflammatory interventions for gout flares and surmised that canakinumab and intravenous or intramuscular corticosteroids are superior to  nonsteroidal antiinflammatory drugs [NSAIDs].

Read Article
RheumNow Podcast square

RheumNow Podcast – Heart, Lung & Liver (5.28.2021)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com.

Read Article
Vaccine2.jpg (keep)

Methotrexate Impairs COVID Vax Response

MedPage Today

One-third of patients with immune-mediated inflammatory diseases being treated with methotrexate showed attenuated responses to the COVID-19 vaccine, researchers reported.

Read Article
pills-3d-render-5-1165365.jpg

Triple DMARD Therapy Bested by Biologics in Swedish Registry

Jack Cush, MD

The Swedish Register compared outcomes of 1502 rheumatoid arthritis (RA) patients initiating either biologics plus methotrexate (MTX) or triple therapy (MTX plus sulfasalazine plus hydroxychloroquine/chloroquine) and showed similar rates of sustained remission.

Read Article
CV,risk,MI,heart,cardiac

CV Risk Decreased with Certain DMARDs in Rheumatoid Arthritis

Jack Cush, MD

A large prospective cohort study examined the comparative risks of cardiovascular disease (CVD) in patients with rheumatoid arthritis (RA) and found that, methotrexate (MTX), abatacept (ABA) and TNF inhibitor (TNFi) use were associated with a decreased risk of CV events. 

Read Article
COVID.Flu_.Virus_.jpg (keep)

Factors Associated with COVID-19 Deaths in Rheumatic Patients

Jack Cush, MD

Analysis of data from the COVID-19 Global Rheumatology Alliance shows that rheumatic diseases infected with COVID-19 had a greater risk of death with age, comorbidities, high disease activity and few specific therapies.

Read Article
RheumNow Podcast square

RheumNow Podcast – Myth Busters (5.21.2021)

Jack Cush, MD

Dr Jack Cush reviews the news and journal reports from the past week on RheumNow.com

Read Article
infx.pneumonia.jpg

Lower Rates of Serious Infection with Ustekinumab in Psoriatic Disease

MedPage Today

Patients with psoriasis or psoriatic arthritis who were being treated with ustekinumab (Stelara) had lower rates of serious hospitalized infections than patients receiving other biologics or small molecule therapies, a study utilizing data from two commercial claims databases found.

Read Article
colonperf.png

Tocilizumab Risk of Diverticulitis and GI Perforation

Jack Cush, MD

A French registry analysis compared the risk of diverticulitis and gastrointestinal perforation (GIP) in rheumatoid arthritis (RA) patients treated with biologics and found a greater risk of both in patients receiving tocilizumab (TCZ) compared with those on rituximab (RTX) or abatacept (ABA

Read Article
Hands-Down Rheumatology - Sarcoidosis usually presents as a monarthritis or oligoarthritis. Late sarcoid arthritis affects knees, ankles, fingers (dactylitis). Bony lesions show honeycomb trabecular pattern). https://t.co/lmXBbJz6ts

Links:

Dr. John Cush RheumNow ( View Tweet)

Top May Tweet: Belimumab now approved in the EU for lupus nephritis. The EMA has approved intravenous and subcutaneous Benlysta (belimumab) in combination with background immunosuppressive therapies for adults with active lupus nephritis https://t.co/Twbe1ClT5w

Links:

Dr. John Cush RheumNow ( View Tweet)

RheumNow Podcast – Heart, Lung & Liver (5.28.2021) Dr Jack Cush reviews the news and journal reports from this past week on RheumNow. https://t.co/a9fvgaJVnQ https://t.co/r3nbf2Ftdb

Links:

Dr. John Cush RheumNow ( View Tweet)
News Feature: CV Risk Decreased with Certain DMARDs in Rheumatoid Arthritis A large prospective cohort study examined the comparative risks of CVD in patients with RA and found that, MTX, ABA & TNFi use were associated w/ a decreased risk of CV events. https://t.co/uQbtB76Hgy https://t.co/ftc5ys9C58

Links:

Dr. John Cush RheumNow ( View Tweet)
Preliminary results from 600 pt SAVE-MORE trial in severe COVID, anakinra + standard-of-care was 55% better than SOC in preventing death or respiratory failure; and improving Hosp Discharge by 4 days. Anakinra Rx 100mg/day up to 10 days https://t.co/vbpUMQjC1o

Links:

Dr. John Cush RheumNow ( View Tweet)

Listen to Dr. Jack Cush review the news and journal reports from the past week on RheumNow. Our latest podcast is available for download on SoundCloud, Apple and Android carplay. https://t.co/FvmmOBAjC1 https://t.co/rrZO6jOlKt

Links:

Dr. John Cush RheumNow ( View Tweet)
Worth sharing again--ARTIC REWIND - Don't Half DMARD Therapy https://t.co/mZFehDM9nf https://t.co/7keyvIHD3R

Links:

Dr. John Cush RheumNow ( View Tweet)
#LupusAwarenessMonth Dr. Mike Putman - TULIP Trials - Anifrolumab in SLE https://t.co/cqZiulDMFm https://t.co/Vo17RfBOSk

Links:

Dr. John Cush RheumNow ( View Tweet)
Real world study of 21 GCA patients over age 80 yrs taking tocilizumab. (for GC-sparing in 14, relapsing Dz in 8, severity in 4, DMARD failure in 4). 8 [2–21] months post-TCZ, 67% were off GCs. AE included 4 Hi Chol, 3 SIE, 2 cytopenia, 1 hi LFTs https://t.co/ER0ROQw4ma

Links:

Dr. John Cush RheumNow ( View Tweet)

Metanalysis (11 RCTs, 19 registries) of Pulm arterial HTN assoc. w/ CTD (w/ 1,267 & 4,008 CTD-PAH pts), showed Investigational Rxs reduced morbidity/mortality by 36%. CTD-PAH survival was lower (62 vs 72%) @3yrs, but improved after 2010 (73 vs 65%) https://t.co/0BkO70AQfi

Links:

Dr. John Cush RheumNow ( View Tweet)

Checkpoint Inhibitor Safety in Melanoma Patients with AID A study from the DMT shows that the use of checkpoint inhibitors for advanced melanoma in AID patients didn't increase the risk of irAEs, except for those with preexisting IBD. https://t.co/VFzBOlc0wc https://t.co/0zfr8YFmZr

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×